文献速递肝病

FGF4通过激活AMPK-Caspase 6信号轴保护肝脏免受非酒精性脂肪性肝病

FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis.
PubMed 文献 · Hepatology · 2022-02-27

本研究探讨FGF4在非酒精性脂肪性肝病(NAFLD)中的作用。人类患者和小鼠模型中肝脏FGF4表达与NAFLD病理分级呈负相关;肝脏Fgf4缺失加重高脂饮食诱导的肝脂肪变性和肝损伤,而重组FGF4给药可减轻小鼠NAFLD和NASH的肝脏脂肪变性、炎症、肝损伤和纤维化标志物,其作用主要通过激活FGFR4-AMPK-Caspase 6信号轴介导。

要点

  • 肝脏FGF4表达与人类和小鼠NAFLD病理分级呈负相关。
  • 肝脏Fgf4缺失加重高脂饮食诱导的小鼠肝脂肪变性和肝损伤。
  • 重组FGF4给药减轻小鼠NAFLD和NASH的肝脏脂肪变性、炎症、肝损伤和纤维化标志物。

核心结论

  • FGF4是肝脏病理生理学的应激反应性调节因子,通过FGFR4-AMPK-Caspase 6信号通路发挥作用,为治疗NAFLD及相关肝脏病理提供策略线索。

研究设计与样本

  • 研究采用人类患者和小鼠模型,检测肝脏FGF4表达与NAFLD病理分级的关系,并通过肝脏Fgf4缺失和高脂饮食诱导NAFLD/NASH模型以及重组FGF4给药进行干预实验。

主要发现

  • 肝脏FGF4表达在人类患者和小鼠模型中均与NAFLD病理分级呈负相关。
  • 肝脏Fgf4缺失加重肥胖性高脂饮食诱导的肝脂肪变性和肝损伤。
  • 重组FGF4给药减轻饮食挑战诱导的小鼠NAFLD和NASH肝脏脂肪变性、炎症、肝损伤和纤维化标志物。
  • FGF4的有益效应主要由激活肝脏FGFR4介导,进而激活下游Ca2+-Ca2+/钙调蛋白依赖性蛋白激酶激酶β依赖的AMPK-Caspase 6信号轴,促进脂肪酸氧化、减少肝细胞凋亡并减轻肝损伤。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: NAFLD represents an increasing health problem in association with obesity and diabetes with no effective pharmacotherapies. Growing evidence suggests that several FGFs play important roles in diverse aspects of liver pathophysiology. Here, we report a previously unappreciated role of FGF4 in the liver. APPROACH AND RESULTS: Expression of hepatic FGF4 is inversely associated with NAFLD pathological grades in both human patients and mouse models. Loss of hepatic Fgf4 aggravates hepatic steatosis and liver damage resulted from an obesogenic high-fat diet. By contrast, pharmacological administration of recombinant FGF4 mitigates hepatic steatosis, inflammation, liver damage, and fibrogenic markers in mouse livers induced to develop NAFLD and NASH under dietary challenges. Such beneficial effects of FGF4 are mediated predominantly by activating hepatic FGF receptor (FGFR) 4, which activates a downstream Ca2+ -Ca2+ /calmodulin-dependent protein kinase kinase beta-dependent AMP-activated protein kinase (AMPK)-Caspase 6 signal axis, leading to enhanced fatty acid oxidation, reduced hepatocellular apoptosis, and mitigation of liver damage. CONCLUSIONS: Our study identifies FGF4 as a stress-responsive regulator of liver pathophysiology that acts through an FGFR4-AMPK-Caspase 6 signal pathway, shedding light on strategies for treating NAFLD and associated liver pathologies.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Song L, Wang L, Hou Y, et al. FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis. Hepatology. 2022. PMID: 35152446. doi:10.1002/hep.32404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。